NCT Number: NCT05806814
Phase: PHASE1
Trial Summary: Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castr – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Oklahoma
Acronym: OUSCCEXCITE
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives